REG - Fusion Antibodies - Contract wins with existing client

Fusion AntibodiesAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250827:nRSa7388Wa&default-theme=true

RNS Number : 7388W  Fusion Antibodies PLC  27 August 2025

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse (amendment)
(EU Exit) Regulations 2019/310 ("MAR"). With the publication of this
announcement via a Regulatory Information Service, this inside information is
now considered to be in the public domain.

 

27 August 2025

 

Fusion Antibodies plc

("Fusion" or the "Company")

 

Contract wins with existing client

 

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody
discovery, engineering and supply for both therapeutic drug and diagnostic
applications, announces that it has been selected to proceed with three follow
on projects to the stable Cell Line Development project (the "CLD Project")
announced on 27 February 2025. The original contract and the follow-on
contracts (the "New Contracts") all operate under a collaborative research and
development agreement (the "Agreement") with a US based biotechnology company
(the "Client").

 

Work in relation to the CLD Project under the original contract was expected
to last between six to nine months. The New Contracts build on the successful
progress to date with the original project, extending its scope and
establishing a further new engineering project for the Client.  The New
Contracts are valued at c. $460,000, of which a minimum of $400,000 is
expected to be recognised in the current financial year ending 31 March 2026.
 

 

Adrian Kinkaid, CEO of Fusion, said: "We are delighted to extend our agreement
with this significant client and to add a further earlier stage project to the
pipeline of work we are undertaking with them. We look forward to continuing
to work with our Client to bring better antibodies to the clinic more rapidly.
These New Contracts and the CLD Project highlights the strong reputation that
Fusion has for delivering high quality therapeutic antibodies and their
associated cell lines: a part of our offering with excellent scope for
growth."

 

Navigate to our Interactive Investor hub here:
https://investorhub.fusionantibodies.com/
(https://investorhub.fusionantibodies.com/) . Engage with us by asking
questions, watching video summaries and seeing what other shareholders have to
say.

 

Enquiries:

 

 Investor questions on this announcement  https://investorhub.fusionantibodies.com/s/b8d633
                                          (https://investorhub.fusionantibodies.com/s/b8d633)
 We encourage all investors to share questions on this announcement via our
 investor hub

 Fusion Antibodies plc                                                                           www.fusionantibodies.com
 Adrian Kinkaid, Chief Executive Officer                                                         Via Walbrook PR

 Stephen Smyth, Chief Financial Officer

 Allenby Capital Limited                                                                         Tel: +44 (0) 20 3328 5656
 James Reeve/Vivek Bhardwaj (Corporate Finance)

 Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)

 Shard Capital Partners LLP
 Damon Heath (Joint Broker)                                                                      Tel: +44 (0) 207 186 9952

 Walbrook PR                                                         Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
                                                                     (mailto:fusion@walbrookpr.com)
 Anna Dunphy                                                                                     Mob: +44 (0)7876 741 001

 

About Fusion Antibodies plc

 

Fusion is a Belfast based contract research organisation ("CRO") providing a
range of antibody engineering services for the development of antibodies for
both therapeutic drug and diagnostic applications.

 

The Company's ordinary shares were admitted to trading on AIM on 18 December
2017. Fusion provides a broad range of services in antibody generation,
development, production, characterisation and optimisation. These services
include antigen expression, antibody production, purification and sequencing,
antibody humanisation using Fusion's proprietary CDRx (TM) platform and the
production of antibody generating stable cell lines to provide material for
use in clinical trials. Since 2012, the Company has successfully sequenced
and expressed over 250 antibodies and successfully completed over 200
humanisation projects and has an international, blue-chip client base, which
has included eight of the top 10 global pharmaceutical companies by revenue.

 

The Company was established in 2001 as a spin out from Queen's University
Belfast. The Company's mission is to enable pharmaceutical and diagnostic
companies to develop innovative products in a timely and cost-effective manner
for the benefit of the global healthcare industry. Fusion Antibodies provides
a broad range of services in antibody generation, development, production,
characterisation and optimisation.

 

Fusion Antibodies growth strategy is based on combining the latest
technological advances with cutting edge science to deliver new platforms that
will enable Pharma and Biotech companies get to the clinic faster, with the
optimal drug candidate and ultimately speed up the drug development process.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTPKABQPBKDCFB